A Focused Question, Not a Cure All
Women produce testosterone naturally, and levels can change with age and ovarian function. But age or a low test result alone does not show that treatment is needed. A clinical discussion should start with a specific concern and consider its possible causes, rather than treating a number in isolation.
Evidence supports considering testosterone for some carefully assessed women with persistent, distressing low sexual desire, or hypoactive sexual desire disorder (HSDD). A 2022 review of guidance on testosterone for women emphasizes assessment before treatment and notes that evidence does not establish testosterone as a general remedy for fatigue, mood, cognition, or other wellness concerns.
At Dermatology Associates, PC, hormone replacement therapy is part of a broader wellness offering, but that does not make testosterone a treatment for every menopause-related change. This section provides general education, not a diagnosis or individual treatment recommendation. A qualified clinician can help assess symptoms, discuss uncertainty and alternatives, and determine whether further evaluation is appropriate.
Menopause and Its Changing Symptoms
Menopause is reached after 12 consecutive months without a menstrual period. It typically occurs between ages 45 and 55, with an average age of about 51 to 52. The transition leading up to it, called perimenopause, can bring changes that start gradually and vary from person to person.
Symptoms may include irregular periods, hot flashes, night sweats, disrupted sleep, mood changes, vaginal dryness, and shifts in sexual desire. Some people experience several of these changes, while others have few or none. Changes in sexual desire can also have overlapping physical, emotional, medication-related, or relationship factors, so they do not by themselves point to one hormonal cause. The International Menopause Society’s discussion of testosterone and sexual desire emphasizes assessing other possible contributors rather than relying on a hormone result alone.
Persistent or concerning symptoms are worth discussing with a healthcare professional, since they can have causes unrelated to menopause and may call for different care. At Dermatology Associates, PC, menopause-related concerns can be discussed within its broader hormone replacement and feminine wellness services, with care plans tailored to a patient’s health and goals.
When Treatment May Be Considered
Testosterone may be considered for some women with hypoactive sexual desire disorder (HSDD), a persistent reduction in sexual desire that causes significant personal distress. A lower level of desire without distress does not, on its own, establish HSDD.
For appropriately assessed postmenopausal women with HSDD, evidence suggests transdermal testosterone can improve sexual desire and satisfying sexual experiences. The VA’s 2025 clinical summary focuses on postmenopausal patients; guidance from the International Society for the Study of Women’s Sexual Health also discusses selected women in the late reproductive stage after assessment.
Expected gains should be realistic. A review of clinical trials reported a modest average benefit, and treatment does not help everyone. Low desire may have several contributors, including health conditions, medications, mood, or relationship factors, so assessment should look beyond hormone levels.
At Dermatology Associates, PC, hormone-related care is part of a broader, personalized wellness approach. Any discussion of testosterone should still be grounded in a qualified clinician’s assessment and a review of potential benefits, risks, and alternatives.
Testosterone is not FDA-approved for women in the United States, so prescribing it for HSDD is off-label and calls for informed shared decision-making. Evidence does not establish it as routine treatment for fatigue, mood or cognitive concerns, aging, or a low test result alone. A blood test cannot by itself diagnose HSDD or show that treatment is appropriate.
Assessment Before Any Prescription
Evaluation begins with a conversation about low desire: when it started, how persistent it is, whether it causes personal distress, and what the patient hopes to change. A clinician may also review medical and surgical history, current medications, and prior sexual health.
The assessment looks beyond hormone levels. Menopause-related symptoms, mood, relationship concerns, painful intercourse, sleep, medication effects, and other medical or psychosocial factors can all affect desire. Guidance on HSDD recommends a biopsychosocial assessment rather than assuming testosterone is the cause (International Menopause Society guidance).
A blood test cannot diagnose HSDD, and a low testosterone result alone does not establish a need for treatment. Testing may provide a baseline and help identify an unexpectedly high level before therapy; it can also support dose safety and follow-up. The VA clinical summary on off-label testosterone likewise describes HSDD as a clinical diagnosis, not a laboratory cutoff.
At Dermatology Associates, PC, hormone replacement therapy is part of a broader wellness practice, so an assessment can consider a patient’s concerns in the context of their health history and goals. Any decision about testosterone should weigh possible benefits against uncertainties, risks, alternatives, and the need for monitoring. The practice’s testosterone therapy options for women offers related patient education.
Guidance and the Limits of Evidence
International and specialty-society guidance supports testosterone as an option for carefully assessed women with hypoactive sexual desire disorder (HSDD), not as a general treatment for menopause symptoms or disease prevention. The strongest evidence applies to postmenopausal women. Recommendations for women in earlier reproductive stages differ, reflecting less settled evidence. The International Society for the Study of Women’s Sexual Health guidance discusses this narrower, symptom-based approach.
A blood test cannot diagnose HSDD or, by itself, show that treatment is appropriate. Testing is used to check baseline levels and help monitor treatment, with the aim of keeping testosterone within the premenopausal physiological range. Routine assays may be imprecise at the low concentrations typical in women, so results need clinical context. The VA’s 2025 clinical summary likewise distinguishes clinical diagnosis from laboratory monitoring.
In the United States, testosterone use for this purpose is generally off-label, and long-term safety evidence remains limited. Decisions should account for symptoms, health history, possible alternatives, and the patient’s preferences. At Dermatology Associates, PC, hormone replacement therapy is part of a broader wellness practice; any testosterone discussion still calls for individualized clinician assessment and follow-up rather than treatment based on a lab result alone.
Formulations Require Careful Use
Testosterone products differ in how they are absorbed and what they are intended to treat. Systemic creams or gels are not interchangeable with vaginal preparations, which may be used for local symptoms and have different absorption. Use only the product and application site prescribed by a clinician.
In the United States, no testosterone product is FDA-approved specifically for women. For carefully assessed patients with HSDD, clinicians may prescribe a product designed for men at a lower, off-label dose. Because these products are packaged for male dosing, accurate measurement matters. The 2025 VA clinical summary describes transdermal treatment and stresses monitoring to keep levels within the premenopausal physiological range.
Compounded testosterone is generally discouraged when suitable alternatives are available because its dose, quality, and effectiveness may be uncertain. Injections, pellets, and oral formulations are also not recommended in guidance for systemic HSDD treatment. These routes can produce excessive levels or make dosing difficult to adjust, particularly when a pellet has already been inserted.
Topical testosterone can transfer from treated skin to other people or pets. Follow the specific product instructions, including washing hands after application, covering the site when directed, and avoiding skin-to-skin contact until it is safe. At Dermatology Associates, PC, hormone-related concerns can be considered alongside its broader wellness and feminine-wellness services, with treatment decisions guided by individual assessment and appropriate clinical monitoring.
Potential Side Effects and Uncertainties
Acne and increased facial or body hair are among the possible androgen-related effects of testosterone therapy. If these appear, a clinician may review the dose; some effects can improve when exposure is reduced. Follow-up can also account for visible skin changes as part of an individualized plan.
Testosterone levels above the usual female range can cause scalp hair thinning, voice deepening, or clitoral enlargement. Some changes, particularly voice and clitoral changes, may not fully reverse. The VA clinical summary on off-label transdermal testosterone emphasizes maintaining levels within the physiologic range and monitoring for signs of excess.
Short-term findings do not settle the question of long-term safety. Evidence on cardiovascular and breast outcomes remains limited, and possible changes in cholesterol or other health measures may lead a clinician to recommend blood tests based on a patient’s history and treatment plan. The International Menopause Society’s discussion of testosterone for HSDD also notes the need for more long-term evidence.
Risk can vary with dose, formulation, duration, and individual health. In the United States, use for women is generally off-label, so patients should review their medical history, potential benefits, alternatives, and monitoring plan with a qualified clinician. Treatment decisions should remain individualized rather than treated as risk-free.
Follow-Up and Measuring Response
Monitoring is a clinician-led part of testosterone therapy, not simply a matter of checking a lab result. Follow-up should consider whether the original symptom has improved, whether unwanted effects have appeared, and whether blood testosterone remains within the expected range for women.
Guidance commonly recommends checking testosterone several weeks after treatment starts or the dose changes, then periodically once levels are stable. For example, the 2025 VA clinical summary recommends an early check and ongoing monitoring, with timing adjusted to the clinical plan. Other tests may be appropriate based on a patient’s health and medical history.
At Dermatology Associates, PC, hormone replacement therapy is part of a broader wellness practice, where care plans are personalized to a patient’s concerns and health context. A clinician may lower the dose or stop treatment if levels become excessive, side effects develop, or there is no meaningful improvement after an adequate trial. The decision should reflect both the patient’s experience and clinical findings.
Some guidance recommends reassessing whether treatment is still needed after six to twelve months. If therapy continues, its benefits and risks should be reviewed regularly rather than assumed to remain unchanged. The appropriate schedule and next steps depend on the individual treatment plan.
Weight Loss Is Not an Indication
Testosterone is not an established or FDA-approved weight-loss treatment for women, and current evidence does not show that it produces meaningful weight loss. A recent VA clinical summary does not recommend testosterone to improve body composition; its evidence review focuses on treatment for hypoactive sexual desire disorder.
Weight gain alone is not a reason to use testosterone. Findings about testosterone and body composition in men with testosterone deficiency cannot be assumed to apply to women, whose treatment evidence and clinical indications differ. Testosterone may be considered for specific sexual-health concerns after assessment, not as a general remedy for weight or aging.
At Dermatology Associates, PC, hormone-related concerns are considered within personalized wellness care rather than treated from a single symptom or lab result. If weight changes are troubling, discuss them with a qualified clinician who can review potential causes, health history, and goals, then consider evidence-based options suited to your circumstances.
A Personalized, Evidence Led Decision
Testosterone may be an option for selected women with persistent, distressing low sexual desire, but it is not a general remedy for menopause, aging, or weight concerns. Symptoms and laboratory results alone cannot establish that treatment is appropriate.
A qualified clinician can help review possible causes, alternatives, uncertain benefits and risks, and whether follow-up is warranted. Dermatology Associates, PC offers hormone and feminine wellness services, but any discussion of testosterone should remain grounded in an individual clinical assessment, not an assumption that a particular product or protocol suits every patient.
